Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy
Executive Summary
Endocyte paid just $12m upfront a year ago for a potential first-in-class investigational radioligand therapy for prostate cancer. Novartis is buying Endocyte for a whopping $2.1bn., highlighting the company's emphasis on building in radiopharmaceuticals.
You may also be interested in...
Novartis Broadens VISION On Radioligands
Phase III trial presented at ASCO shows 177lutetium-PSMA-617 improved radiographic PFS and OS in advanced prostate cancer patients. Novartis execs say the firm is ready for the marketing challenge.
Lead From The Front – But Resist Micromanaging
Theragnostics’ CEO Greg Mullen aims to use his wide-ranging “hands-on” scientific and commercial experience to help clinch a $45m series A financing round that will fund a Phase I/II basket study to develop the biotech’s lead radiotherapeutic PARP inhibitor.
The Medicines Company Rises On Novartis Takeover Rumors
It's been a good week for the US company with its PCSK9 gene-silencing drug impressing at the American Heart Association meeting and reports that Novartis is close to making a bid.